Hilton Santa Fe Historic Plaza Hotel Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2017
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
PI3K Pathways in Immunology, Growth Disorders and Cancer (A6)
Organizer(s) Leon O. Murphy, Klaus Okkenhaug and Sabina C. Cosulich
January 19—23, 2017
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, NM USA
Discounted Abstract Deadline: Sep 21, 2016
Abstract Deadline: Oct 19, 2016
Scholarship Deadline: Sep 21, 2016
Discounted Registration Deadline: Nov 16, 2016
Sponsored by Bayer HealthCare Pharmaceuticals, Cell Signaling Technology, Inc., Incyte Corporation and Pfizer Inc.
Summary of Meeting:
The overall goal for this meeting is to bring together scientific leaders and trainees with a common interest in PI3Ks and relevant downstream physiological processes. It will address advances in basic molecular and cellular mechanisms that are regulated by PI3Ks, other PI kinases and, their cognate phosphatases; highlight new advances in the characterization of PI3K pathway alterations in genetic syndromes that affect growth and the immune and nervous systems; and provide an important update on the clinical development of PI3K pathway inhibitors, and implications for the burgeoning field of cancer immunotherapy. Whole exome sequencing studies have increasingly implicated PI3K signaling in diseases (immune, growth and neurological disorders) which may benefit from drugs currently in development for cancer and inflammation. This meeting will be an important forum for discussing approaches to treating these additional disorders.
View Scholarships/Awards
The overall goal for this meeting is to bring together scientific leaders and trainees with a common interest in PI3Ks and relevant downstream physiological processes. It will address advances in basic molecular and cellular mechanisms that are regulated by PI3Ks, other PI kinases and, their cognate phosphatases; highlight new advances in the characterization of PI3K pathway alterations in genetic syndromes that affect growth and the immune and nervous systems; and provide an important update on the clinical development of PI3K pathway inhibitors, and implications for the burgeoning field of cancer immunotherapy. Whole exome sequencing studies have increasingly implicated PI3K signaling in diseases (immune, growth and neurological disorders) which may benefit from drugs currently in development for cancer and inflammation. This meeting will be an important forum for discussing approaches to treating these additional disorders.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Thursday, January 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 23 with a closing plenary session and keynote address from 17:00 to 20:15, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 24 in order to fully experience the meeting.
THURSDAY, JANUARY 19
FRIDAY, JANUARY 20
SATURDAY, JANUARY 21
SUNDAY, JANUARY 22
MONDAY, JANUARY 23
TUESDAY, JANUARY 24
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Thursday, January 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 23 with a closing plenary session and keynote address from 17:00 to 20:15, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 24 in order to fully experience the meeting.
THURSDAY, JANUARY 19
08:00—11:15
PI3K Function and Physiology
*
Lewis C. Cantley,
Weill Cornell Medicine, USA
*
Doreen A. Cantrell,
University of Dundee, UK
Len R. Stephens,
Babraham Institute, UK
Signaling via Class I PI3Ks
Signaling via Class I PI3Ks
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
Physiological Roles of PI3K Isoforms
Physiological Roles of PI3K Isoforms
Coffee Break
Jeffery L. Kutok,
Epizyme, Inc., USA
The PI3K-gamma Inhibitor, IPI-549, Increases Antitumor Immunity by Targeting Tumor-Associated Myeloid Cells and Overcomes Immune Checkpoint Blockade Resistance in Preclinical Tumor Models
The PI3K-gamma Inhibitor, IPI-549, Increases Antitumor Immunity by Targeting Tumor-Associated Myeloid Cells and Overcomes Immune Checkpoint Blockade Resistance in Preclinical Tumor Models
John E. Burke,
University of Victoria, Canada
Short Talk: Conformational Disturbance of PI3Kdelta Regulation by Primary Immunodeficiency Mutations in PIK3CD and PIK3R1
Short Talk: Conformational Disturbance of PI3Kdelta Regulation by Primary Immunodeficiency Mutations in PIK3CD and PIK3R1
Kyle A. Edgar,
Genentech, Inc., USA
Short Talk: The PI3K Inhibitor, Taselisib, has Enhanced Potency in PIK3CA Mutant Models Through a Unique Mechanism of Action
Short Talk: The PI3K Inhibitor, Taselisib, has Enhanced Potency in PIK3CA Mutant Models Through a Unique Mechanism of Action
17:00—19:00
PI3K Effectors
*
Sabina C. Cosulich,
AstraZeneca Oncology, UK
*
Igor Vivanco,
Institute of Cancer Research, UK
Brendan D. Manning,
Harvard School of Public Health, USA
The TSC-Rheb-mTOR Circuit and Metabolic Control
The TSC-Rheb-mTOR Circuit and Metabolic Control
David A. Fruman,
University of California, Irvine, USA
The mTORC1/4E-BP/eIF4E Axis in B-Cell Activation and Transformation
The mTORC1/4E-BP/eIF4E Axis in B-Cell Activation and Transformation
John Blenis,
Weill Cornell Medical College, USA
mTORC1/S6K1: Regulation of RNA Biogenesis, Protein Synthesis and Cell Metabolism
mTORC1/S6K1: Regulation of RNA Biogenesis, Protein Synthesis and Cell Metabolism
Ivan Yudushkin,
Medical University of Vienna, Austria
Short Talk: Membrane Subpopulations of mTORC2 Display Distinct Sensitivity to PI3K
Short Talk: Membrane Subpopulations of mTORC2 Display Distinct Sensitivity to PI3K
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Phosphatases
*
Len R. Stephens,
Babraham Institute, UK
*
Brendan D. Manning,
Harvard School of Public Health, USA
Ramon Parsons,
Icahn School of Medicine at Mount Sinai, USA
PTEN Upstream, Instream and Downstream
PTEN Upstream, Instream and Downstream
Lloyd Trotman,
Cold Spring Harbor Laboratory, USA
PTEN Function and Loss of Function in Prostate Metastasis
PTEN Function and Loss of Function in Prostate Metastasis
Coffee Break
Christina Anne Mitchell,
Monash University, Australia
New Roles for Inositol Polyphosphate Phosphatases
New Roles for Inositol Polyphosphate Phosphatases
Doreen A. Cantrell,
University of Dundee, UK
Phosphatidylinositol-3-Kinase Control of T Lymphocyte Differentiation: Dogma Versus Reality
Phosphatidylinositol-3-Kinase Control of T Lymphocyte Differentiation: Dogma Versus Reality
Ana Clara Carrera,
Centro Nacional Biotechnologia/CSIC, Spain
Short Talk: PI3K Depletion Induces Tumor Regression; E-Cadherin Downregulation Sensitizes PTEN-Mutant Tumors to PI3K-Beta Silencing
Short Talk: PI3K Depletion Induces Tumor Regression; E-Cadherin Downregulation Sensitizes PTEN-Mutant Tumors to PI3K-Beta Silencing
Sarah E. Conduit,
University College London, UK
Short Talk: INPP5E Regulates Murine SHH Medulloblastoma
Short Talk: INPP5E Regulates Murine SHH Medulloblastoma
14:30—16:30
Workshop 1: PI3K, Metabolism and Stress Pathways
*
Kyle A. Edgar,
Genentech, Inc., USA
*
John E. Burke,
University of Victoria, Canada
Jack Flanagan,
University of Auckland, New Zealand
Evidence of a New Mechanism for Achieving PI3K Inhibition with Small Molecules via an Effect on Membrane Binding
Evidence of a New Mechanism for Achieving PI3K Inhibition with Small Molecules via an Effect on Membrane Binding
Erika Ilagan,
Harvard T.H. Chan School of Public Health, USA
The TSC-Rheb-mTORC1 Circuit is a Shared Effector of PI3K-Akt and Ras-Erk Signaling
The TSC-Rheb-mTORC1 Circuit is a Shared Effector of PI3K-Akt and Ras-Erk Signaling
Gina Lee,
Weill Cornell Medicine, USA
mTORC1-S6K1 Regulation of SR Protein Kinase Links mRNA Biogenesis to De Novo Lipid Synthesis
mTORC1-S6K1 Regulation of SR Protein Kinase Links mRNA Biogenesis to De Novo Lipid Synthesis
Marie H. Solheim,
Joslin Diabetes Center, Harvard Medical School, USA
Conserved p85alpha SH2 Domain Residues Play Differential Roles in p85alpha-IRS-1 Binding
Conserved p85alpha SH2 Domain Residues Play Differential Roles in p85alpha-IRS-1 Binding
Lukasz Pawel Magiera,
University of Cambridge, UK
Pik3ca Gain-of-Function Mutation Restricted to Mesenchymal Cells Expressing Fibroblast Activation Protein-Alpha Causes Skeletal Overgrowth
Pik3ca Gain-of-Function Mutation Restricted to Mesenchymal Cells Expressing Fibroblast Activation Protein-Alpha Causes Skeletal Overgrowth
17:00—19:00
Class II/III PI3Ks
*
Jonathan M. Backer,
Albert Einstein College of Medicine, USA
Volker Haucke,
Leibniz Forschungsinstitut für Molekulare Pharmakologie, Germany
Phosphoinositide Conversion in the Endolysosomal System
Phosphoinositide Conversion in the Endolysosomal System
Leon O. Murphy,
Casma Therapeutics, USA
Role of VPS34 in Cancer Growth and Autophagy
Role of VPS34 in Cancer Growth and Autophagy
Emilio Hirsch,
Fondazione per la Ricerca Biomedica – ONLUS, Italy
Class II PI3K in Mitosis
Class II PI3K in Mitosis
Wei-Xing Zong,
Rutgers University, USA
Short Talk: PI3-Kinase p110beta Regulates Cell Metabolism and Oncogenesis by Promoting Endocytic Turnover of Nutrient Transporters
Short Talk: PI3-Kinase p110beta Regulates Cell Metabolism and Oncogenesis by Promoting Endocytic Turnover of Nutrient Transporters
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Signaling from Non-Canonical PI Kinases
*
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
*
Klaus Okkenhaug,
University of Cambridge, UK
Brooke M. Emerling,
Sanford Burnham Prebys Medical Discovery Institute, USA
PI5P4Ks and Cancer Metabolism
PI5P4Ks and Cancer Metabolism
Pietro V. De Camilli,
Yale University School of Medicine, USA
Phosphoinositide Dynamics at the Plasma Membrane
Phosphoinositide Dynamics at the Plasma Membrane
Coffee Break
Nullin Divecha,
University of Southampton, UK
Phosphoinositides and Nuclear Signaling
Phosphoinositides and Nuclear Signaling
Tamas Balla,
NICHD, National Institutes of Health, USA
Phosphatidylinositol 4-Kinases: Keys to Lipid Transport and Metabolism
Phosphatidylinositol 4-Kinases: Keys to Lipid Transport and Metabolism
Miguel Murillo,
Institute of Cancer Research, UK
Short Talk: Disrupting RAS-PI3K Interaction Promotes EFGR-Induced Tumor Regression Abrogating RAC1-Mediated Positive Feedback Loop
Short Talk: Disrupting RAS-PI3K Interaction Promotes EFGR-Induced Tumor Regression Abrogating RAC1-Mediated Positive Feedback Loop
Sreenivasa R. Chinni,
Wayne State University, USA
Short Talk: PI4KIII Alpha-CXCR4 Axis Cross-Talk in Prostate Cancer Promotes Cell Invasion
Short Talk: PI4KIII Alpha-CXCR4 Axis Cross-Talk in Prostate Cancer Promotes Cell Invasion
15:00—16:30
Panel: Career Development
This panel will include an established PI, a new PI, an industry scientist and will facilitate an interactive session on early career development for scientists.
*
Leon O. Murphy,
Casma Therapeutics, USA
Brooke M. Emerling,
Sanford Burnham Prebys Medical Discovery Institute, USA
Suchithra Menon,
Novartis, USA
Pamela L. Schwartzberg,
NIAID, NHGRI, National Institutes of Health, USA
17:00—19:00
Overgrowth Syndromes
*
Edith M. Hessel,
GlaxoSmithKline, UK
*
Leon O. Murphy,
Casma Therapeutics, USA
Robert K. Semple,
University of Edinburgh, UK
Human Disorders of Growth due to Type 1A PI3K Mutations
Human Disorders of Growth due to Type 1A PI3K Mutations
Kathleen Millen,
Seattle Children's Research Institute, USA
The Role of PIK3CA in Megalencephaly and Epilepsy
The Role of PIK3CA in Megalencephaly and Epilepsy
Cameron C. Trenor III,
Boston Children's Hospital, USA
Overgrowth and Vascular Anomalies: PIK3CA Heterogeneity and Sirolimus Responses
Overgrowth and Vascular Anomalies: PIK3CA Heterogeneity and Sirolimus Responses
Ghayda Mirzaa,
Seattle Children's Hospital, USA
Short Talk: Mosaic and Constitutional Mutations of the PI3K-AKT-MTOR Pathway are Associated with a Wide Spectrum of Developmental Brain Disorders from Focal Cortical Dysplasia to Diffuse Megalencephaly with Autism
Short Talk: Mosaic and Constitutional Mutations of the PI3K-AKT-MTOR Pathway are Associated with a Wide Spectrum of Developmental Brain Disorders from Focal Cortical Dysplasia to Diffuse Megalencephaly with Autism
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
PI3K in Immunity and Infection
*
David A. Fruman,
University of California, Irvine, USA
Klaus Okkenhaug,
University of Cambridge, UK
Class I PI3K Isoforms and Mutants in Immunity, Infection and Cancer
Class I PI3K Isoforms and Mutants in Immunity, Infection and Cancer
Pamela L. Schwartzberg,
NIAID, NHGRI, National Institutes of Health, USA
PIK3CD and Immunodeficiency
PIK3CD and Immunodeficiency
Coffee Break
Laurence A. Turka,
Rheos Medicines, USA
PI3K Signaling and Metabolism in Regulatory T Cells
PI3K Signaling and Metabolism in Regulatory T Cells
Edith M. Hessel,
GlaxoSmithKline, UK
Developing PI3K Inhibitors for COPD and Respiratory Disease
Developing PI3K Inhibitors for COPD and Respiratory Disease
Christoph Burkhart,
Novartis Institutes for BioMedical Research, Switzerland
Short Talk: The PI3K-Delta Inhibitor CDZ173 (leniolisib) Rescues the Immune Cell Defects and Improves the Clinical Course in Patients with Activated PI3K-delta Syndrome (APDS)
Short Talk: The PI3K-Delta Inhibitor CDZ173 (leniolisib) Rescues the Immune Cell Defects and Improves the Clinical Course in Patients with Activated PI3K-delta Syndrome (APDS)
Carrie L. Lucas,
Yale University, USA
Short Talk: Human Immune Dysregulation Caused by Mutations in the Gene Encoding the p110g PI3K Subunit
Short Talk: Human Immune Dysregulation Caused by Mutations in the Gene Encoding the p110g PI3K Subunit
14:30—16:30
Workshop 2: PI3K in Immune Disorders and Immuno-Oncology
*
Carrie L. Lucas,
Yale University, USA
*
Christoph Burkhart,
Novartis Institutes for BioMedical Research, Switzerland
Honyin Chiu,
University of California, Irvine, USA
A Novel Role for the 4E-BP/eIF4E Axis in B Cell Antibody Class Switching
A Novel Role for the 4E-BP/eIF4E Axis in B Cell Antibody Class Switching
Elissa K. Deenick,
Garvan Institute of Medical Research, Australia
Over Activation of PI3K Causes Defects In B-Cell Development and Differentiation
Over Activation of PI3K Causes Defects In B-Cell Development and Differentiation
Anne-Katrien Stark,
Babraham Institute, UK
PI3Kdelta Hyper-Activation Results in Increased Susceptibility to S. Pneumoniae Airway Infection
PI3Kdelta Hyper-Activation Results in Increased Susceptibility to S. Pneumoniae Airway Infection
Maria Gonzalez-Nunez,
Queen Mary University of London, UK
The Role of p110delta PI3K Signaling in NOD2-Mediated Gastrointestinal Immunity and Inflammation
The Role of p110delta PI3K Signaling in NOD2-Mediated Gastrointestinal Immunity and Inflammation
Aimé Cézaire Adiko,
Center for Research on Inflammation/ Paris University, France
Opposite Effects of two PI3K Gamma Regulatory Subunits in Dendritic Cells
Opposite Effects of two PI3K Gamma Regulatory Subunits in Dendritic Cells
Anita Chandra,
Babraham Institute, UK
B Cell Function and Development in the Context of PI3Kdelta Hyper-Activation
B Cell Function and Development in the Context of PI3Kdelta Hyper-Activation
Sarah H. Ross,
Babraham Institute, UK
Understanding the Regulation of PI(3,4,5)P3 Levels in Effector Cytotoxic T Lymphocytes
Understanding the Regulation of PI(3,4,5)P3 Levels in Effector Cytotoxic T Lymphocytes
17:00—18:30
PI3K and Oncology
*
John Blenis,
Weill Cornell Medical College, USA
Mika Derynck,
Genentech, Inc., USA
Clinical Drug Development of PI3K Pathway Inhibitors in Solid Tumors: Threading the Needle for a Therapeutic Index
Clinical Drug Development of PI3K Pathway Inhibitors in Solid Tumors: Threading the Needle for a Therapeutic Index
Sabina C. Cosulich,
AstraZeneca Oncology, UK
Clinical Development of mTOR Inhibitors
Clinical Development of mTOR Inhibitors
Jennifer R. Brown,
Dana-Farber Cancer Institute, USA
Clinical Development of PI3K Inhibitors for CLL
Clinical Development of PI3K Inhibitors for CLL
18:30—19:15
Closing Keynote Address
*
Leon O. Murphy,
Casma Therapeutics, USA
Lewis C. Cantley,
Weill Cornell Medicine, USA
PI3K and Cancer Metabolism
PI3K and Cancer Metabolism
20:15—21:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:15—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
